BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

The quest for BARD1’s ELISA test takes another step forward.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

The BARD1 Life Sciences Ltd (ASX: BD1) share price has walked through today’s session in the green.

Before the open, BARD1 updated investors on a significant milestone in the development of its ELISA diagnostics test.

Let’s investigate further.

A quick recap on BARD1 Life Sciences

BARD1 is a clinical diagnostics business with a focus on developing detection tests in a range of various cancers.

In addition, BARD1 also has a heavy interest in the research and development of non-invasive diagnostic tests for the early detection of cancer.

At the time of writing, BARD1 has a market capitalisation of $128 million.

What did BARD1 announce?

The company announced it had achieved proof of concept for its enzyme-linked immunosorbent assay (ELISA) based test for ovarian cancer.

BARD1’s research partner at Griffith University showed how an initial ELISA test can detect a key biomarker found in tumour cells “from stages I–IV ovarian cancer”.

Moreover, the ELISA test demonstrated it could detect the biomarker with “100% sensitivity and specificity” compared to the control group.

This is important because the test needs to “do what it says on the tin”. That’s to distinguish the biomarker in cases of ovarian cancer, not in “healthy controls” as BARD1 puts it.

As a result, it seems the outcome is a win for the ELISA regime, described as a “low-cost assay that can be performed in commercial laboratories worldwide”, as per the release.

Moving forward, Griffith University and BARD1 will now “advance to the optimisation phase” for the ELISA test.

What did management say?

Referencing the data, BARD1 chief scientific officer, Dr Peter French said:

These data represent a key go decision to progress the optimisation and validation of our SubB2M ELISA-based tests that are expected to improve existing cancer biomarker tests for ovarian, breast, prostate and other cancers.

BARD1 Life Sciences share price snapshot

The BARD1 Life Sciences share price has climbed 114% into the green this year to date, extending the gain over the previous 12 months by 62%.

These results have outpaced the S&P/ASX 200 Index (ASX: XJO)’s return of around 25% over the past year.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a man with a wry smile is behind ascending piles of coins as he places another coin on top of the tallest stack.
Share Market News

Can ASX 200 banks really see a 15% profit jump if the cash rate hits 1%?

These analysts are predicting big returns for banks in the rising interest rate environment.

Read more »

An office worker and his desk covered in yellow post-it notes
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Wednesday

We take a look at the most traded ASX 200 shares by volume today.

Read more »

an oil refinery worker checks her laptop computer in front of a backdrop of oil refinery infrastructure. The woman has a serious look on her face.
Energy Shares

ASX 200 energy shares in focus amid frightening global supply crisis

A dearth of new fossil fuel projects in recent years has opened the door to today's global energy crisis.

Read more »

A happy man and woman sit having a coffee in a cafe while she holds up her phone to show him the ASX shares that did best today
Share Market News

ASX 200 midday update: BlueScope and Fortescue rise, Boral tumbles

The ASX 200 is having a strong day on Wednesday...

Read more »

A man standing in a red rock mine is covered by a sheet of gold blowing in the wind.
Gold

What’s sending the Northern Star share price higher today?

The gold miner reported it will return 20% to 30% of cash earnings as dividend payouts at its investor presentation,…

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Share Market News

Warren Buffett’s been bargain hunting following the stock market sell-off. Here’s the sector he’s been buying (and selling)

We check the investing guru's recent buys and sells.

Read more »

Share Market News

5 things to watch on the ASX 200 on Wednesday

A strong day is expected on the ASX 200 on Wednesday...

Read more »

top 10 asx shares today
Share Market News

Here are the top 10 ASX shares today

Here are your top 10 biggest gainers in the ASX 200 on Tuesday.

Read more »